Investors find safety in J&J shares, but run could stall
(Reuters) – After lagging a 6-year healthcare sector run fueled by fast-growing biotech companies, Johnson & Johnson (NYSE:JNJ) shares have beaten the group in 2016 as investors turn to safety in rocky equity markets.
But with the stock price now hovering near its $110.35 record high, that strategy may be in doubt. J&J shares already have risen to the level that the average analyst has targeted for them, and sell at a healthy premium to large pharmaceutical companies such as Pfizer (NYSE:PFE) and Merck (NYSE:MRK). Relative to their own future earnings, the shares are more expensive than they have been in more tha...
Source: Mass Device - April 14, 2016 Category: Medical Equipment Authors: MassDevice Tags: Business/Financial News Johnson & Johnson newtag Source Type: news
Two Anti-TNFs Effective in Immune Uveitis (CME/CE)
(MedPage Today) -- Overall response rates were 97% and 95% for infliximab and adalimumab (Source: MedPage Today Ophthalmology)
Source: MedPage Today Ophthalmology - April 9, 2016 Category: Opthalmology Source Type: news
A Rocky Start for Biosimilar Inflectra?
(MedPage Today) -- Infliximab biosimilar approved, but obstacles remain (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 7, 2016 Category: Primary Care Source Type: news
Rheumatology community responds to FDA approval of Inflectra (Infliximab-dyyb), a Biosimilar to Remicade
The ACR has issued an official statement regarding the FDA's approval of Inflectra (infliximab-dyyb), a biosimilar to Remicade. Inflectra is the first biosimilar to receive approval in the U.S. for the treatment of rheumatic diseases, including rheumatoid arthritis and psoriatic arthritis. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 7, 2016 Category: Science Source Type: news
Inflectra Approved as 'Biosimilar' to Remicade
Title: Inflectra Approved as 'Biosimilar' to RemicadeCategory: Health NewsCreated: 4/6/2016 12:00:00 AMLast Editorial Review: 4/7/2016 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - April 7, 2016 Category: Rheumatology Source Type: news
FDA Approves Biosimilar to Treat Immune-Mediated Conditions (FREE)
By Kelly Young
Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, FASAM
The FDA has approved Inflectra (infliximab-dyyb) to treat several immune-mediated disorders.Inflectra is biosimilar to … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 6, 2016 Category: Primary Care Source Type: news
FDA approves biosimilar competition for J&J's Remicade drug
The Food and Drug Administration granted marketing approval to Inflectra, a biosimilar product to Horsham-based Janssen Biotech’s multibillion-dollar Remicade drug.
Janssen Biotech, which formerly operated as Centocor, is a subsidiary of Johnson & Johnson (NYSE: JNJ).
Inflectra, the second biosimilar product approved by the FDA, will be co-marketed by Celletrion, a Korean drug company and Pfizer (NYSE:PFE)
The FDA action allows Inflectra to be marketed as a treatment for some, but not all, of… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 6, 2016 Category: Biotechnology Authors: John George Source Type: news
FDA Approves 2nd Biosimilar for J&J's Remicade
The U.S. FDA approved Inflectra (infliximab-dyyb) for multiple indications, and it is administered by intravenous infusion. This is the second biosimilar approved by the FDA. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - April 6, 2016 Category: Pharmaceuticals Source Type: news
Inflectra Approved as 'Biosimilar' to Remicade
For adults with Crohn's, rheumatoid arthritis or psoriasis (Source: U.S. News - Health)
Source: U.S. News - Health - April 6, 2016 Category: Consumer Health News Source Type: news
FDA approves biosimilar to Remicade for arthritis, IBS
Stephen FellerBETHESDA, Md., April 6 (UPI) -- Inflectra, a drug similar to Remicade, but cheaper, is expected to hit the market in 2016, helping patients with arthritis, IBS and other chronic conditions. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 6, 2016 Category: Consumer Health News Source Type: news
Inflectra Approved as 'Biosimilar' to Remicade
WEDNESDAY, April 6, 2016 -- The U.S. Food and Drug Administration has approved its second-ever "biosimilar" drug, Inflectra, for adults with Crohn's disease, rheumatoid arthritis or chronic plaque psoriasis, among other prescribed uses.
In a media... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 6, 2016 Category: Journals (General) Source Type: news
FDA Approves Inflectra, a Biosimilar to Remicade
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 6, 2016 Category: Journals (General) Source Type: news
Business Briefing: F.D.A. Clears Cheaper Version of Johnson & Johnson Biologic
Federal officials have approved a cheaper version of Johnson & Johnson’s blockbuster drug Remicade, a biotech medicine for inflammatory diseases. (Source: NYT Health)
Source: NYT Health - April 6, 2016 Category: Consumer Health News Authors: THE ASSOCIATED PRESS Tags: Johnson & Drugs (Pharmaceuticals) Food and Drug Administration Remicade (Drug) Celltrion Biotechnology and Bioengineering Pfizer Inc Generic Brands and Products Source Type: news
FDA Approves Remicade Biosimilar (Inflectra)FDA Approves Remicade Biosimilar (Inflectra)
The second biosimilar approved in the United States, this version of infliximab is indicated for Crohn's disease, rheumatoid arthritis, and almost all other conditions listed for the original. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 5, 2016 Category: Consumer Health News Tags: Internal Medicine News Alert Source Type: news
